Piramed Pharma: The Benefit of Focus




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Piramed Pharma: The Benefit of Focus
Released on: October 01, 2007. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this exclusive interview, Fintan Walton talks to Khatereh Ahmadi, Business Development Director at the UK biotech Piramed Pharma, about the company’s formation following a collaboration between Yamanouchi Pharmaceutical (now Astellas Pharma), Cancer Research UK, the Institute of Cancer Research and the Ludwig Institute.
  • Summary
  • Participants
  • Company
In this exclusive interview, Fintan Walton talks to Khatereh Ahmadi, Business Development Director at the UK biotech Piramed Pharma, about the company’s formation following a collaboration between Yamanouchi Pharmaceutical (now Astellas Pharma), Cancer Research UK, the Institute of Cancer Research and the Ludwig Institute. Khatereh discusses the IP in PI 3-kinases (phosphoinositide 3-kinases) that Piramed gained from that collaboration, and goes on to detail the nature and extent of the company’s collaboration with Genentech. She also outlines the company’s strategy going forward and the challenges faced by early-stage biotechs such as Piramed.
Khatereh Ahmadi was a post-doctoral scientist in the laboratory of Mike Waterfield and subsequently branch Scientific Programme Manager at the Ludwig Institute for Cancer Research, University College, London. In the latter capacity, Khatereh managed a 7-year collaboration between the Institute and a major pharmaceutical company which subsequently licensed IP to Piramed, and she played a significant role in setting up the company with the founders. She managed the PI 3-kinase drug discovery project within Piramed until December 2004, after which she took on a full-time role in Business Development with responsibility for licensing, commercial contracts and IP management. Khatereh received her higher education at King’s College, London where she obtained a bachelor’s degree in Biotechnology and a PhD in Immunology following an interim period in scientific publishing.
Piramed Pharma